Home Health Lancet pays attention to cardiovascular safety of Hanmi’s ‘Epeglenatide’

Lancet pays attention to cardiovascular safety of Hanmi’s ‘Epeglenatide’

by news dir

[FETV=김창수 기자] The world-renowned medical journal Lancet published a meta-analysis study including global clinical results, including the cardiovascular safety of Efpeglenatide, a biologic drug developed by Hanmi Pharm, in its October issue.

Efpeglenatide is a once-weekly dosage form biologic drug developed by Hanmi Pharmaceutical for the treatment of GLP-1 diabetes. It is based on the research results.

According to the published paper, Professor Navid Sata of the University of Glasgow, UK, and colleagues performed a meta-analysis of the cardiovascular benefit and risk ratio (HR) of GLP-1 receptor agonists in type 2 diabetes. The research team used clinical data from a total of 680 patients from 8 studies that met appropriate criteria, including cardiovascular mortality assessment, in studies in which more than 500 patients were enrolled among GLP-1 related papers published by June 2021.

The research team included the epeglenatide AMPLITUDE-O clinical trial in this study, further demonstrating the cardiovascular safety of GLP-1 drugs, as well as being the first exendin-4 based GLP-1 receptor agonist to develop 3-point MACE (cardiovascular disease). It has also been shown to reduce mortality, myocardial infarction, and stroke).

The research team found a statistically significant result that GLP-1 receptor agonists also reduced the hospital admission rate for heart failure in diabetic patients by 11%, suggesting the possibility of creating a new innovation for efeglenatide.

The researchers also confirmed that the once-weekly GLP-1 receptor agonist, such as efeglenatide, was nearly as effective as the daily treatment.

The epeglenatide AMPLITUDE-O clinical trial was led by Sanofi and is a phase 3 clinical trial announced at the American Diabetes Association (ADA) in June. This is a study in which 4mg or 6mg of efeglenatide was administered alone to 4076 patients with type 2 diabetes or cardiovascular disease in 344 regions in 28 countries. Compared to the placebo group, the incidence of major cardiovascular events was reduced by 27% and the incidence of kidney disease by 32%.

“It is significant that efeglenatide, one of the most widely used GLP-1 receptor agonists in the world, contributed to the encouraging results of this meta-analysis study,” said Kwon Se-chang, president of Hanmi Pharmaceutical. We will do our best to present the potential for creating new innovations for efeglenatide, which has secured cardiovascular safety as well as other benefits.”


Related Articles

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.